目的探讨非小细胞肺癌组织中Sirt1的表达及其对患者预后的影响。方法收集264例非小细胞肺癌手术治疗患者的临床病理资料和术后生存随访资料，通过免疫组化的方法检测Sirt1的表达，分析其与患者临床病理指标及预后之间的关系。结果 Sirt1在非小细胞肺癌组织中明显高于周围正常肺组织，差异具有统计学意义（P＜0.05），并且在肿瘤组织（尤其是鳞状细胞癌）中Sirt1表达越高，患者预后越差。而与年龄、性别、肿瘤组织学类型、分化程度、淋巴结转移、远处转移、临床TNM分期等无明显关系（均P＞0.05）。结论 Sirt1在非小细胞肺癌（尤其鳞癌）组织中的表达水平有望成为预测非小细胞肺癌患者预后的生物标志物。%Objective To investigate the expression of Sirt1 in non-small-cel lung cancer (NSCLC) and its clinicopatho-logical significance. Methods The clinicopathological data of 225 patients with NSCLC admitted in Zhejiang Hospital from 2002 to 2010 were retrospectively reviewed. Immunohistochemistry was used to examine the expression of Sirt1 in specimens of lung cancer and pericancerous tissue. The correlations of Sirt1 expression with clinicopathological features and survival of patients were analyzed. Results The expression of Sirt1 was significantly higher in cancerous tissues than that in adjacent noncancerous tissues. The expression of Sirt1 was significantly correlated with overal survival of patients, particularly in patients with squamous cel carcinoma;however, it was not correlated with the age, gender of patients and the histological classification, differentiation, tumor size, lymph node metastasis, distant metastasis and TNM stage of the cancer. Conclusion Sirt1 might be a novel biomarker for prognosis of patients with non-smal cel lung cancer.
展开▼
